Skip to main content
Complete Olympic Games coverage at your fingertips
Your inside track on the Olympic Games
Enjoy unlimited digital access
$1.99
per week for 24 weeks
Complete Olympic Games coverage at your fingertips
Your inside track onthe Olympics Games
$1.99
per week
for 24 weeks
// //

A vial of Moderna's COVID-19 vaccine in Topeka, Kansas, on Dec. 30, 2020.

Charlie Riedel/The Associated Press

A second COVID-19 vaccine won regulatory approval in Europe on Wednesday and the Netherlands belatedly launched its vaccination campaign as European countries accelerated a patchy drive to defeat the coronavirus pandemic.

The green light for Moderna Inc’s vaccine from the European Medicines Authority (EMA), and later the European Commission, was a big boost for European hopes of containing a disease that has infected more than 85 million people globally and killed nearly 1.9 million.

“With the Moderna vaccine, the second one now authorized in the EU, we will have a further 160 million doses. And more vaccines will come,” said Ursula von der Leyen, who heads the European Union executive.

Story continues below advertisement

The EMA granted conditional marketing approval two weeks ago for a similar vaccine from U.S. company Pfizer Inc and German partner BioNTech SE.

The Pfizer/BioNTech vaccine has been given to hundreds of thousands of Europeans since rollout began a week ago though the campaign has been uneven, with officials in Germany and France frustrated at the slow rate of progress.

An EU official told Reuters on Wednesday that the EMA could shortly approve an amendment to its approval of the Pfizer-BioNTech vaccine that would permit the extraction of six doses from a vial instead of five.

The source, who asked to remain anonymous because discussions are not public, said the change to the authorization could come “very soon.”

The change could add a requirement for the use of special syringes that allow the precise extraction of more doses from the same vial, the official said.

The Moderna vaccine will help accelerate vaccination campaigns in Europe as concerns grow about two more infectious variants of the virus, detected in South Africa and Britain, which have driven a surge in cases.

Governments in many countries face growing public criticism for appearing slow to curb the spread of the virus, including the Netherlands, which started its vaccination drive a week after many other EU member states.

Story continues below advertisement

Sanna Elkadiri, a 39-year-old nurse who looks after dementia patients at a care home in the south of the country, received a shot of the Pfizer-BioNTech vaccine.

“This is the beginning of the end of this crisis,” Health Minister Hugo de Jonge said at a brief ceremony.

Dutch Prime Minister Mark Rutte said his government had been preparing for a vaccine developed by Oxford University and AstraZeneca to be approved first, and this had reduced the Dutch authorities’ flexibility.

TEST FOR EUROPE

The vaccine rollout has been a test of Brussels’ ability to unify Europe amid political pressure to speed up the process.

Some EU member states fretted over the length of time the EMA took to decide on the Pfizer-BioNTech shot, leaving it lagging the United States, Britain, Israel and Switzerland in approving and administering the first vaccines.

The regulator has given conditional marketing approval – rather than the ultra-fast emergency use approval issued by Britain, saying more detailed study of the data is required.

Story continues below advertisement

The European Commission defended its actions, saying it had been important not to put all its eggs in one basket when various vaccines were still at development stage.

“We always knew that it would be a complex operation and this is precisely why the European Commission was so adamant that it was important we could sign contracts with different companies,” spokesman Eric Mamer said.

The two-dose Moderna vaccine – which can be stored and transported more easily than the Pfizer-BioNTech vaccine – has already been rolled out in the United States and Canada, and Israel this week granted authorization.

It was about 95 per cent effective at preventing illness in clinical trials that found no serious safety issues.

With COVID-19 cases continuing to surge worldwide, the World Bank has warned that rising infections and delays in vaccine distribution could limit the global economic recovery to growth of just 1.6 per cent this year.

GOVERNMENTS UNDER FIRE

More people in the United States are now hospitalized with COVID-19 than at any time since the global pandemic began, according to a Reuters tally of public health data, and state and local officials face growing pressure to speed up vaccine distribution.

Story continues below advertisement

China, where the first cases of the novel coronavirus were identified in December 2019, on Wednesday imposed travel restrictions and banned gatherings in the capital city of Hebei province, which surrounds Beijing.

Although Britain was the first country to approve and start administering the Pfizer-BioNTech vaccine, Prime Minister Boris Johnson’s government has been accused by political opponents of indecision after England began a new lockdown this week.

The French government has come under fire after its inoculation campaign began slowly, hampered by red tape and President Emmanuel Macron’s decision to tread warily in one of the world’s most vaccine-skeptical countries.

France is now stepping up its vaccine rollout and experts say a third national lockdown should be ruled out.

Germany has decided to extend a nationwide lockdown until the end of this month and to introduce tougher restrictions. But Finance Minister Olaf Scholz said Europe’s biggest economy could hold out for a long time.

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies